3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Leukemia, Myeloid, Acute
124
Multiple Myeloma
83
Precursor Cell Lymphoblastic Leukemia-Lymphoma
74
Lymphoma
73
Lymphoma, Non-Hodgkin
65
Leukemia
65
Myelodysplastic Syndromes
56
Hodgkin Disease
53
Lymphoma, Large B-Cell, Diffuse
37
Lymphoma, Mantle-Cell
33
Breast Neoplasms
31
Leukemia, Lymphocytic, Chronic, B-Cell
30
Burkitt Lymphoma
30
Neuroblastoma
29
Lymphoma, Follicular
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26
Recurrence
24
Sarcoma
18
Neoplasms, Plasma Cell
18
Hematologic Neoplasms
18
Central Nervous System Neoplasms
18
Lymphoma, B-Cell, Marginal Zone
17
Leukemia, Biphenotypic, Acute
16
Myeloproliferative Disorders
15
Lymphoma, Large-Cell, Immunoblastic
15
Congenital Abnormalities
15
Brain Neoplasms
14
Leukemia, Myelomonocytic, Chronic
13
Anemia, Refractory, with Excess of Blasts
13
Medulloblastoma
12
Interventions
pegylated granulocyte colony-stimulating factor, human
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Chemotherapy Induced Neutropenia
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01674855
2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 3
Completed
74 enrolled
NCT01923545
2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 2
Completed
61 enrolled